Trials / Active Not Recruiting
Active Not RecruitingNCT07143227
A Study of XW003 Injection in Chinese Adolescents With Obesity
A Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of XW003 Injection in Chinese Adolescents With Obesity
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd. · Industry
- Sex
- All
- Age
- 12 Years – 18 Years
- Healthy volunteers
- Accepted
Summary
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW003 injection in Chinese adolescents with obesity
Detailed description
In this study, eligible participants will be randomized into one of the three cohorts in a 3:1 ratio to receive either once-weekly subcutaneous XW003 injection or placebo, for up to 20 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XW003 injection | Subcutaneous injection |
| DRUG | placebo with matching volume | Subcutaneous injection |
Timeline
- Start date
- 2025-08-25
- Primary completion
- 2026-06-30
- Completion
- 2026-12-31
- First posted
- 2025-08-27
- Last updated
- 2026-04-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07143227. Inclusion in this directory is not an endorsement.